Biocept appoints samuel d. riccitelli as interim president and chief executive officer and antonino morales as interim chief financial officer

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, announces the appointments of samuel d. riccitelli as interim president and chief executive officer, succeeding michael w. nall, and antonino morales as interim chief financial officer, succeeding timothy c. kennedy. biocept also named m. faye wilson as lead independent director of the company's board of directors. mr. riccitelli remains chair of the board. “i am g
BIOC Ratings Summary
BIOC Quant Ranking